Table 2.
Patient Characteristics for those in NSABP LTS-01 Longitudinal Sample by Treatment
| Characteristic | FULV | FLOX | P* (FULV vs. FLOX) |
|---|---|---|---|
|
| |||
| No. of Patients (%) | No. of Patients (%) | ||
| N | 42 | 50 | |
| Age, years | |||
| < 50 | 11 (26.2) | 9 (18.0) | 0.72 |
| 50-59 | 15 (35.7) | 17 (34.0) | |
| 60-69 | 12 (28.6) | 17 (34.0) | |
| ≥ 70 | 4 (9.5) | 7 (14.0) | |
| Sex | |||
| Male | 30 (71.4) | 30 (60.0) | 0.25 |
| Female | 12 (28.6) | 20 (40.0) | |
| Positive Nodes | |||
| 0 | 15 (35.7) | 15 (30.0) | 0.17 |
| 1-3 | 19 (45.2) | 31 (62.0) | |
| 4+ | 8 (19.1) | 4 (8.0) | |
| Site | |||
| Left Colon | 10 (23.8) | 10 (20.0) | 0.22 |
| Right Colon | 17 (40.5) | 29 (58.0) | |
| Sigmoid | 15 (35.7) | 11 (22.0) | |
Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project; LTS-01, Long-Term Survivors study; FULV, fluorouracil and leucovorin; FLOX, FULV plus oxaliplatin.
*
P-value from χ2 test of independence.